Evidence map›Paper›PMID 38927933›Full record

ArticleCancers2024

Audiological Outcomes of Weekly vs. Triweekly Cisplatin in Head and Neck Cancer with Cochlear-Sparing Intensity-Modulated Radiation Therapy.

Mauricio E Gamez, Dukagjin M Blakaj, Priyanka Bhateja, Amy Custer, Brett G Klamer, Jeff Pan, Emile Gogineni, Sujith Baliga, Marcelo R Bonomi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mauricio E GamezDepartment of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN 55905, USA.
Dukagjin M BlakajDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Priyanka BhatejaDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0001-9515-0498
Amy CusterOncology Rehabilitation Team, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Brett G KlamerCenter for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jeff PanCenter for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Emile GogineniDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0001-6222-311X
Sujith BaligaDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0002-8032-2071
Marcelo R BonomiDepartment of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0002-9399-3608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin, one of the most ototoxic anti-neoplastic agents, causes permanent hearing loss in up to 90% of patients. We assessed ototoxicity rates and prospectively collected audiologic outcomes of patients receiving low-dose or high-dose cisplatin with concurrent cochlear-sparing intensity-modulated radiation therapy (IMRT). Patients with head and neck squamous cell carcinoma (HNSCC) receiving definitive or adjuvant cisplatin-based chemoradiotherapy (CRT) were analyzed. Cisplatin was administered either in low doses weekly (40 mg/m

Indexed as

adverse eventsaudiological outcomeshead and neck cancerhigh-dose cisplatinIMRTototoxicityweekly cisplatin

Identifiers

PMID38927933
PMCPMC11201991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.